NCT05237258|RecruitingDMC
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
SCOPE-L
Loading search results
SCOPE-L
Sponsor study identifier
interventional
2,300
1 country
20
Study Start
June 1, 2022
Actual (reported)Primary Completion
April 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
April 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 2, 2022
Actual (reported)February 14, 2022
Actual (reported)June 1, 2022
Actual (reported)April 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
April 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Quality of Life (QOL)
Establish that primary palliative care is non-inferior to specialty palliative care in patient-reported quality of life (QOL) as measured by the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leukemia) over 12 weeks. Higher scores on FACT-Leukemia (range 0-176) indicate a better QOL.
Over 12 weeks
Patient Quality of Life (QOL)
Up to 2 Weeks
Patient Depression Symptoms
Up to 12 Weeks
\- Participants will complete baseline self-report assessments at the time of informed consent
\- Participants will complete baseline self-report assessments at the time of informed consent
Participants assigned to specialty palliative care will be cared for by both oncology and palliative care clinicians during their hospital stays for AML.
Participants assigned primary palliative care will be cared for by oncology clinicians who have been trained in palliative care during the hospital stays for AML.
University of Alabama - Birmingham
Birmingham, Alabama, 35294, United States
Stanford University
Stanford, California, 94305, United States
Areej El-Jawahri, MD
Massachusetts General Hospital
Jennifer Temel, MD
Massachusetts General Hospital
First Submitted
February 2, 2022
First Posted
February 14, 2022
Study Start
June 1, 2022
Actual (reported)Primary Completion
April 2028
EstimatedTriggered Palliative Care for Advanced Dementia
Patient Anxiety Symptoms
Up to 12 Weeks
Patient Post-Traumatic Stress Disorder (PTSD) Symptoms
Up to 12 Weeks
End-of-Life (EOL) Communication
Up to 12 Weeks
Patient Prognostic Understanding
Up to 24 weeks
Patient Coping
Up to 24 weeks
Hospitalization
Last 30 days of life
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
University of Colorado Denver I Anschutz Medical Campus
Denver, Colorado, 80204, United States
University of Miami
Miami, Florida, 33146, United States
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Emory University
Atlanta, Georgia, 30322, United States
Northwestern University
Evanston, Illinois, 60208, United States
Indiana University
Bloomington, Indiana, 47405, United States
Johns Hopkins University
Baltimore, Maryland, 21218, United States
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Mayo Clinic
Rochester, Minnesota, 55905, United States
University of Rochester
Rochester, New York, 14627, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Duke University
Durham, North Carolina, 27708, United States
Ohio State University
Columbus, Ohio, 43210, United States
Oregon Health & Science University
Portland, Oregon, 97239, United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
University of Wisconsin
Madison, Wisconsin, 53715, United States
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
April 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
July 25, 2025
Record last verified: 2025-07
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: